Global Oral Hypoglycemic Agents Ohas Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 61.20 Billion |
 Market Size (Forecast Year) |
USD 83.75 Billion |
 CAGR |
% |
| Major Markets Players |
Global Oral Hypoglycemic Agents (OHAs) Market, By Type of Product (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), End Users (Hospital, Clinics) – Industry Trends and Forecast to 2030.
Oral Hypoglycemic Agents (OHAs) Market Analysis and Size
Oral Hypoglycemic Medications are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes. Diabetes is a metabolic disorder in which patients suffer from high blood glucose level than normal levels in an individual. These rises in blood sugar level are due to the body’s cells do not respond properly to insulin or due to inadequate insulin production. Diabetes is characterized by two types; insulin-dependent diabetes mellitus (type 1) and non-insulin-dependent diabetes mellitus (type 2). The most common symptoms of diabetes are increased thirst, frequent urination, weight and muscle loss, blurred vision, delayed wound healing, and fatigue. The increase in the prevalence of diabetes is an act at a major driver of the oral hypoglycemic agents (OHAs) market.
Data Bridge Market Research analyses that the Oral hypoglycemic agents (OHAs) Market which was USD 61.20 billion in 2022, would rocket up to USD 83.75 billion by 2030, and is expected to undergo a CAGR of 4.00% during the forecast period. “Metformin” dominates the type of product segment of the oral hypoglycemic agents (OHAs) market owing to their therapeutic efficacy and minimal side effects. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Oral Hypoglycemic Agents (OHAs) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type of Product (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), End Users (Hospital, Clinics) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Sanofi (France), Ganlee (China), Biocon (India), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Tonghua Dongbao Pharmaceutical Co., Ltd. (China), Wanbang Biopharmaceuticals (China), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceuticals Limited (Japan), Merck Sharp & Dohme Corp. (MSD) (U.S.), AstraZeneca (U.K.), Janssen Global Services, LLC (a subsidiary of Johnson & Johnson) (Belgium), Boehringer Ingelheim Ltd. (Germany) |
|
Market Opportunities |
|
Market Definition
Oral hypoglycemic agents (OHAs) are medications used to manage and control blood sugar levels in individuals with diabetes. They are taken orally, making them a convenient treatment option for many patients. These drugs work by either increasing insulin production, improving insulin sensitivity, or reducing glucose production in the liver. They play a vital role in diabetes management, helping to prevent complications and maintain healthy blood sugar levels.
Global Oral Hypoglycemic Agents (OHAs) Market Dynamics
Drivers
- Increasing Prevalence of Diabetes
The global prevalence of diabetes is on the rise, primarily driven by factors such as sedentary lifestyles, unhealthy diets, and obesity. As the number of people diagnosed with diabetes increases, so does the demand for effective oral hypoglycemic agents. The expanding patient pool drives market growth for these medications.
- Technological Advancements
Continuous research and development in the field of diabetes management have led to the introduction of new and improved oral hypoglycemic agents. Technological advancements, such as the development of novel drug delivery systems, innovative formulations, and enhanced mechanisms of action, contribute to market growth by providing more effective and patient-friendly treatment options.
Opportunities
- Development of novel drug formulations
The market growth presents an opportunity for pharmaceutical companies to invest in the development of novel drug formulations. This includes extended-release formulations, combination therapies, and innovative drug delivery systems that enhance patient compliance, convenience, and efficacy.
Restraints/Challenges
- Limited Efficacy in Some Patients
While oral hypoglycemic agents are effective for many individuals with diabetes, they may not provide adequate glycemic control for all patients. Some individuals may require additional treatment modalities, such as insulin therapy or combination therapy. The limited efficacy in certain patient populations poses a challenge and highlights the need for personalized treatment approaches.
This Oral hypoglycemic agents (OHAs) Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Oral hypoglycemic agents (OHAs) Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2022, Novo Nordisk, a Danish company, announced the launch of oral semaglutide in India for the treatment of type 2 diabetes.
Global Oral hypoglycemic agents (OHAs) Market Scope
The oral hypoglycemic agents (OHAs) market is segmented on the basis of the type of product and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type of Product
- Sulfonylureas
- Metformin
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Immunotherapy
End users
- Hospitals
- Clinics
Oral hypoglycemic agents (OHAs) Market Regional Analysis/Insights
The Oral hypoglycemic agents (OHAs) Market is analysed and market size insights and trends are provided by country, type of product and end users as referenced above.
The countries covered in the oral hypoglycemic agents (OHAs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to account for the largest market share due to the increased consumption of oral hypoglycemic agents for the treatment of diabetes.
Asia-Pacific is expected to account for the fastest growing market and is expected to account for the largest market share over coming years for the oral hypoglycemic agents (OHAs) market due to the rising prevalence of diabetes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The oral hypoglycemic agents (OHAs) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for oral hypoglycemic agents (OHAs) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the oral hypoglycemic agents (OHAs) market. The data is available for the historic period 2015-2020.
Competitive Landscape and Oral hypoglycemic agents (OHAs) Market Share Analysis
The oral hypoglycemic agents (OHAs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the oral hypoglycemic agents (OHAs) market.
Some of the major players operating in the oral hypoglycemic agents (OHAs) market are:
- Sanofi (France)
- Ganlee (China)
- Biocon (India)
- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
- Wanbang Biopharmaceuticals (China)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Takeda Pharmaceuticals Limited (Japan)
- Merck Sharp & Dohme Corp. (MSD) (U.S.)
- AstraZeneca (U.K.)
- Janssen Global Services, LLC (a subsidiary of Johnson & Johnson) (Belgium)
- Boehringer Ingelheim Ltd. (Germany)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
